| Years ended September 30, | ||||||||
| 2017 | 2016 | |||||||
| Current tax provision | ||||||||
| Federal | $ | - | $ | - | ||||
| State | 1,600 | 1,840 | ||||||
| Total current tax provision | 1,600 | 1,840 | ||||||
| Deferred provision (benefit) | ||||||||
| Federal | 166,600 | (159,800 | ) | |||||
| State | 29,400 | (28,200 | ) | |||||
| Total deferred provision (benefit) | 196,000 | (188,000 | ) | |||||
| Provision (benefit) for income taxes | $ | 197,600 | $ | (186,160 | ) | |||
| Years ended September 30, | ||||||||
| 2017 | 2016 | |||||||
| Income taxes computed at the federal statutory rate | $ | (231,000 | ) | $ | (499,000 | ) | ||
| Change in valuation allowance | 197,000 | (66,000 | ) | |||||
| Expired net operating loss carryforwards | 283,000 | 487,000 | ||||||
| Nondeductible compensation, interest expense and other | 21,000 | 99,000 | ||||||
| State income taxes, net of federal tax benefit | (24,000 | ) | (36,000 | ) | ||||
| Change in R&D credit carryover | (98,000 | ) | (98,000 | ) | ||||
| Stock options and other prior year true-ups | 48,000 | (75,000 | ) | |||||
| Other | 1,600 | 1,840 | ||||||
| Provision (benefit) for income taxes | $ | 197,600 | $ | (186,160 | ) | |||
| At September 30, | ||||||||
| Deferred tax assets: | 2017 | 2016 | ||||||
| Net operating loss carryforwards | $ | 16,443,000 | $ | 16,410,000 | ||||
| Research and development credit | 2,559,000 | 2,461,000 | ||||||
| Share-based compensation | 898,000 | 598,000 | ||||||
| Equipment | (80,000 | ) | (23,000 | ) | ||||
| Patents | 69,000 | 102,000 | ||||||
| Accruals and other | 546,000 | 832,000 | ||||||
| State tax deduction | (7,000 | ) | (7,000 | ) | ||||
| Federal AMT Credit | 52,000 | 52,000 | ||||||
| Allowances | 157,000 | 211,000 | ||||||
| Gross deferred tax asset | 20,637,000 | 20,636,000 | ||||||
| Less valuation allowance | (12,306,000 | ) | (12,109,000 | ) | ||||
| Total deferred tax assets, net of valuation allowance | $ | 8,331,000 | $ | 8,527,000 | ||||